HMGCR and cystic kidney disease: HMGCR inhibition may modulate signaling pathways, such as the mTOR and Wnt/β-catenin pathways, which are known to be hyperactive in cystic kidney diseases, thereby potentially influencing cyst formation and progression [17–20].